This pioneering approach stems from mounting evidence highlighting the gut-brain axis as a critical mediator not only of digestive health but also of brain function and neurological disease progression. Historically, studies investigating this axis have been hampered by the lack of physiologically relevant in vitro models that integrate neural, vascular, and gastrointestinal components in a single cohesive system. By successfully fabricating a three-dimensional platform that co-cultures gut epithelial cells, brain organoids, and vascular structures, Tran, Jeong, An, and colleagues have filled a significant gap, opening avenues to dissect how signals traverse these compartments bidirectionally and influence neuropathogenesis.

Central to the platform’s innovation is its architecture, which recapitulates the spatial and functional complexity of the gut-brain interface. Utilizing state-of-the-art biofabrication techniques, the researchers engineered a microenvironment where gut epithelial cells grow on one chamber, mimicking the intestinal lumen, while cerebral organoids derived from human pluripotent stem cells occupy an adjacent chamber, connected via microfluidic channels lined with endothelial cells that simulate vascular pathways. This design allows soluble factors, immune components, and even microbial metabolites to transit naturally, thereby replicating the physiological cross-talk observed in vivo.

The vasculature element is particularly crucial, addressing a frequently overlooked player in gut-brain communication. Blood vessels serve as conduits for molecular signals, immune cells, and inflammatory mediators, all of which contribute to neuropathological conditions. By integrating endothelial cell networks into the platform, the team has created a dynamic and responsive system capable of reflecting the vascular contributions to neuroinflammation and neurodegeneration that have been increasingly recognized in diseases like Parkinson’s and Alzheimer’s.

Validation experiments further demonstrated the platform’s realistic simulation capacity. The researchers exposed the system to microbial metabolites commonly present in dysbiotic gut conditions, observing critical changes in neural activity and inflammatory gene expression within the brain organoids. These changes paralleled pathological markers identified in patients suffering from neurodegenerative diseases, thus confirming the model’s relevance. Moreover, the vascular component displayed endothelial activation and increased permeability, reminiscent of blood-brain barrier disruption frequently seen in neuropathological states.

One powerful application of this platform lies in unraveling the mechanistic underpinnings whereby gut dysbiosis fosters neuroinflammation and neuronal damage. Prior animal studies have implicated gut microbiota imbalance as a catalyst for neurodegenerative processes, but translating these findings into human biology has remained a challenge. This 3D model serves as a transformative bridge, enabling real-time observation of how microbial-derived signals instigate endothelial dysfunction and neuronal impairment, and how these changes, in turn, feedback on gut epithelium integrity.

Equally important is the platform’s capacity for drug screening and therapeutic testing. Its human-relevant layout allows pharmacological agents to be evaluated for efficacy and toxicity across multiple interconnected tissues simultaneously. This multi-organ approach transcends traditional mono-cellular assays, offering insights into systemic drug impacts, potential adverse vascular or gastrointestinal effects, and the ability to modulate neuro-immune communication. Such comprehensive drug evaluation is crucial for developing treatments targeting complex disorders rooted in gut-brain axis malfunction.

The involvement of human-derived cerebral organoids marks a significant leap forward from rodent models, providing species-specific insights into neural responses that better predict clinical outcomes. These brain organoids contain diverse neuronal cell types arranged in layers resembling the cerebral cortex, offering a sophisticated platform to study neuronal connectivity, synaptic activity, and neurodegeneration hallmarks. Their interaction with gut epithelial cells and vascular networks within the microfluidic device captures the multidimensional pathology underpinning gut-induced neuropathogenesis.

Moreover, the bidirectionality illuminated in this system challenges outdated models assuming unidirectional communication from brain to gut. The platform reveals a reciprocal dialogue where gut disturbances can initiate central nervous system changes and vice versa, emphasizing the need to consider both origins in designing diagnostics and treatments. This nuanced understanding underscores the complexity of neurodegenerative and neuropsychiatric disorders and the necessity of integrative biomedical models.

Attention to microenvironmental parameters, such as shear stress, oxygen gradients, and extracellular matrix composition within the platform, further adds realism. These factors critically influence cell behavior in vivo and were carefully calibrated to maintain tissue health and function. This meticulous engineering assures that observations reflect genuine physiological reactions rather than artifacts, enhancing confidence in the platform’s translational potential for clinical research.

Additionally, the platform’s modularity ensures adaptability to incorporate other relevant cell types, including immune cells, which are pivotal in gut-brain axis dynamics. Future iterations may embed microglia or peripheral immune components to deepen the model’s applicability to neuroinflammatory disorders. This flexibility also holds promise for personalized medicine, where patient-derived cells could inform individualized disease modeling and drug response assessments.

Beyond basic science, this platform may revolutionize biomarker discovery. The ability to monitor real-time molecular exchanges and cell responses across the gut-brain interface offers a rich source of candidate molecules detectable in circulating fluids, which could serve as early indicators of neurological dysfunction originating in the gut. Such biomarkers would be invaluable for early diagnosis and monitoring of disease progression.

In sum, the development of this 3D gut-brain-vascular platform signifies a paradigm shift in neuroscience and gastroenterology research. It embodies a convergence of bioengineering, stem cell technology, and microfluidics to tackle the intricate interplay driving neuropathogenesis. As this model gains traction, it is expected to accelerate breakthroughs that inform both preventive and therapeutic strategies for diseases historically challenging to understand and treat due to their multifactorial nature.

The interdisciplinary effort behind this work exemplifies how integrating diverse scientific domains can overcome entrenched research bottlenecks. By faithfully recreating human gut-brain-vascular interactions in vitro, Tran, Jeong, An, and their collaborators have set the stage for new discoveries that will illuminate the shadowy corridors linking gut health to brain disease. As this platform is refined and adopted widely, it promises a transformative impact on how we study, diagnose, and ultimately combat neurological disorders at their roots.

Their research not only underscores the critical significance of bidirectional communication but also spotlights the vascular system’s previously underappreciated role as a conduit and regulator of gut-brain signaling. This finding could revise existing dogma and catalyze novel therapeutic avenues centered on vascular modulation. As we deepen our comprehension of these intersecting networks, the prospect of mitigating devastating neuropathologies through targeted interventions at the gut-brain-vascular nexus moves closer to reality.

Indeed, the integration of vascular elements represents a timely and visionary approach, considering emerging evidence that vascular dysfunction often precedes overt neurological symptoms. The platform’s ability to capture early vascular responses to gut perturbations offers hope for identifying preclinical markers and intervention points, which could transform patient outcomes through earlier and more effective treatments.

In conclusion, this 3D gut-brain-vascular platform exemplifies the forefront of biomedical innovation. By faithfully modeling the complex, bidirectional crosstalk essential for gut-neuropathogenesis, it delivers a versatile and powerful tool to unravel the multifaceted etiology of neurological diseases. As the scientific community embraces and expands upon this model, it will undoubtedly catalyze transformative insights with far-reaching implications for human health.

Subject of Research: Gut-brain axis, neuropathogenesis, 3D tissue engineering, vascular biology, neuroinflammation, neurodegeneration.

Article Title: A 3D gut-brain-vascular platform for bidirectional crosstalk in gut-neuropathogenesis.

Article References:
Tran, M., Jeong, H.W., An, M. et al. A 3D gut-brain-vascular platform for bidirectional crosstalk in gut-neuropathogenesis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69318-y

Image Credits: AI Generated

Dr. Segal’s research career is marked by groundbreaking contributions to gene-editing technologies, including Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and CRISPR/Cas9-based platforms. These technologies represent a revolutionary toolkit enabling precise and efficient editing of genetic information within living cells, opening unprecedented possibilities for correcting mutations that underlie a myriad of human diseases. His pioneering work has helped to lay the foundation for translating genome editing from a conceptual framework into powerful clinical applications.

Joining the UC Davis faculty in 2005, Segal has been instrumental in redefining what is possible in treating disorders once considered untreatable. His laboratory is particularly focused on neurological and genetic diseases, where his expertise in molecular engineering is creating new therapeutic strategies to target dysfunctional genes. For instance, by developing tools that can reactivate silenced genes or correct gene dosage abnormalities, Dr. Segal’s research addresses fundamental molecular mechanisms that could potentially reverse debilitating disease phenotypes.

Among the rare genetic disorders targeted by Segal’s lab are Angelman syndrome, SYNGAP1 deficiency, ADNP syndrome, neurofibromatosis type 1, and other neurodevelopmental and neurodegenerative conditions. These diseases, while rare individually, collectively affect a larger population than more common conditions such as cancer or AIDS and yet suffer from a critical lack of effective treatments. This stark reality drives Segal’s commitment to not only advancing basic science but also fostering therapeutic innovations that can be broadly accessible to patients in need.

The impact of Segal’s work extends beyond the lab bench into deep collaborations with patient communities. In particular, his interactions with families affected by Angelman syndrome have provided a poignant perspective on the human dimension of rare diseases. This interface between scientific innovation and patient advocacy informs his approach and magnifies the importance of translating molecular research into real-world therapies that reflect patients’ hopes and urgent needs.

Dean Susan Murin of the UC Davis School of Medicine praised Dr. Segal’s appointment, citing his visionary leadership, innovative research program development, and unwavering dedication to mentoring the next generation of scientists. Murin also expressed gratitude for the interim leadership of Dr. Luis Fernando Santana, whose stewardship of the department has been instrumental during the transition period since 2021.

Throughout his career, Segal has authored or co-authored over 120 peer-reviewed publications, and he holds 25 patents, reflecting his substantial contributions to scientific knowledge and technology development. His work has been supported by numerous prestigious grants from the National Institutes of Health (NIH), the California Institute for Regenerative Medicine (CIRM), as well as awards from various foundations and nonprofit organizations focusing on genetic and neurological disorders.

In addition to his roles within the UC Davis School of Medicine, Dr. Segal serves as an investigator with the NIH Somatic Cell Genome Editing Consortium, a major collaborative effort aimed at accelerating somatic genome editing in therapeutic applications. He also holds the position of field chief editor for Frontiers in Genome Editing, a peer-reviewed journal that highlights cutting-edge advancements in the field and fosters discourse around novel gene-editing methodologies.

Dr. Segal’s educational background includes a Bachelor of Science in biology with honors from Cornell University and a Ph.D. in biochemistry from the University of Utah. He conducted postdoctoral research in molecular biology at the Scripps Research Institute in La Jolla, California before embarking on his academic career. Prior to his appointment at UC Davis, he served as an assistant professor in the Department of Pharmacology and Toxicology at the University of Arizona, Tucson.

Within UC Davis, Segal has held several leadership roles that have strengthened interdisciplinary research and graduate education, including co-chairing the Integrative Genetics and Genomics graduate program and serving as associate director of the UC Davis Genome Center. His vision as chair will undoubtedly continue to propel the department to national and international prominence in biomedical research and education.

Segal’s appointment comes at a time when molecular therapeutics and genome editing are rapidly advancing toward clinical reality, promising transformative treatments for diseases previously deemed “incurable.” His work exemplifies the convergence of innovative molecular engineering, patient-centered research, and institutional leadership poised to shape the future of medicine.

With his groundbreaking research and visionary leadership, Dr. David J. Segal is set to lead the UC Davis Department of Biochemistry and Molecular Medicine into a new era of scientific discovery and therapeutic innovation, advancing the frontiers of genome editing to develop novel, accessible treatments for severe genetic and neurological disorders.

Subject of Research: Genome Engineering, Molecular Therapeutics, Rare Genetic and Neurological Disorders
Article Title: David J. Segal Takes Helm at UC Davis Biochemistry and Molecular Medicine Department, Driving Next-Generation Genome Editing Therapies
News Publication Date: Not specified
Web References:
– UC Davis School of Medicine: https://health.ucdavis.edu/medical-school/
– Department of Biochemistry and Molecular Medicine: https://health.ucdavis.edu/biochem/
– Genome Editing Technologies: https://pubmed.ncbi.nlm.nih.gov/21828278/ (ZFNs), https://pubmed.ncbi.nlm.nih.gov/23508559/ (TALENs), https://medlineplus.gov/genetics/understanding/genomicresearch/genomeediting/ (CRISPR/Cas9)
– UC Davis Genome Center: https://genomecenter.ucdavis.edu/
– UC Davis MIND Institute: https://health.ucdavis.edu/mind-institute/
– NIH Somatic Cell Genome Editing Consortium: https://commonfund.nih.gov/editing
– Frontiers in Genome Editing: https://www.frontiersin.org/journals/genome-editing
– Angelman Syndrome Information: https://angelman.org/about-angelman-syndrome/
– SYNGAP1 Deficiency: https://www.childneurologyfoundation.org/disorder/syngap1-related-disorder/
– ADNP Syndrome: https://medlineplus.gov/genetics/condition/adnp-syndrome/
– Neurofibromatosis Type 1: https://www.ctf.org/nf1/

References: Not explicitly listed but available via linked scientific publications and Google Scholar: https://scholar.google.com/citations?user=s1cRNHIAAAAJ&hl=en&oi=ao

Image Credits: UC Davis School of Medicine

Keywords: Gene therapy, Gene editing, Genome engineering, Biochemistry, Molecular therapeutics, Rare diseases, Neurological disorders, CRISPR, ZFNs, TALENs, Angelman syndrome, Neurodevelopmental disorders

Tay-Sachs and Sandhoff diseases are rooted in mutations that cripple lysosomal enzyme function, key facilitators of cellular cleanup and recycling processes. Despite being rare, these conditions wreak profound neurological devastation, often leading to death within the first few years of life. Intriguingly, while neuron deterioration drives symptoms, immune cells in the brain called microglia paradoxically exhibit enzyme levels up to a thousand times higher than neurons. This conundrum led scientists to hypothesize that restoring normal lysosomal enzyme activity within microglia could indirectly rescue neurons, potentially slowing or halting disease progression.

Historically, attempts to correct these enzymatic deficits have involved hematopoietic stem cell transplantation—a procedure that eliminates the patient’s immune system, followed by intravenous infusion of healthy stem cells intended to repopulate the brain with functional microglia. Yet, the approach has been mired by toxic preconditioning regimens, limited cell engraftment in the brain, and serious immune-related side effects including graft-versus-host disease, where donor immune cells attack the recipient’s tissues. Furthermore, such transplants require genetically matched donors to minimize rejection, complicating and delaying treatment.

The Stanford research team, led by Professor Marius Wernig and postdoctoral researcher Marius Mader, sought to circumvent these barriers by pioneering a brain-specific transplantation protocol that spares patients from systemic toxicity and immune complications. By combining localized brain irradiation with administration of a microglia-depleting agent, they created an open niche within the brain for new cells. This approach was complemented by the direct intracerebral injection of microglia precursor cells derived from non-genetically matched donors. To further prevent immune rejection, the scientists administered targeted immunosuppressive drugs to curtail activation of host immune cells that typically destroy foreign cells.

This meticulously orchestrated sequence achieved unprecedented engraftment: over 85% of microglia in treated mice brains were replaced by donor-derived cells persisting for at least eight months post-transplant. Remarkably, this was accomplished without full-body immune system ablation or graft-versus-host complications, demonstrating a safer, more clinically feasible alternative to traditional transplantation.

Mice afflicted with Sandhoff disease exhibited significant improvements following treatment. Whereas untreated controls survived a median of approximately 135 days, treated animals lived up to 250 days, with extended survival accompanied by restored motor functions and normal exploratory behaviors. While eventual hind leg paralysis occurred, the preservation of neurological function for an extended period represents a monumental leap in therapeutic potential.

A fascinating discovery emerged upon closer examination of tissue interactions: the corrected microglia appeared to secrete lysosomal enzymes into the extracellular environment, allowing neighboring neurons—still genetically deficient—to uptake these enzymes. This points to a previously underappreciated role of microglia in supporting neuronal health beyond their traditional immunological functions, suggesting that the success of this therapy hinges not solely on cell replacement but also on intercellular biochemical support.

From a translational perspective, the researchers emphasize the clinical promise of their approach, as each component—brain irradiation, microglia depletion, and immunosuppression—is already utilized in human medicine, potentially accelerating regulatory approval and adoption. Crucially, the use of non-genetically matched donor cells obviates the need for laborious and costly personalized genetic engineering for each patient, paving the way for an “off-the-shelf” cell therapy accessible to many.

Professor Wernig notes that their work addresses three critical challenges in treating lysosomal storage diseases: establishing efficient and durable brain-specific engraftment without toxic conditioning, employing unmatched donor cells capable of enzyme production without genetic modification, and circumventing immune rejection and graft-versus-host disease. This trifecta of innovations could transform the therapeutic landscape for patients with Tay-Sachs, Sandhoff, and potentially a broader range of neurodegenerative disorders.

Indeed, the implications may extend far beyond rare childhood diseases. The researchers speculate that lysosomal dysfunction observed in disorders like Alzheimer’s and Parkinson’s diseases might represent accelerated or analogous pathophysiological processes. If so, microglia replacement therapy could usher in a new era of treatment for common adult neurodegenerative diseases, offering hope to millions affected worldwide.

As the study advances toward human trials, it embodies a remarkable convergence of stem cell biology, immunology, and neuroscience. It exemplifies how a detailed understanding of cellular interactions within the brain microenvironment can inspire therapies that restore not merely cell populations but the intricate biochemical interdependencies vital for neural function.

This breakthrough reinvigorates optimism for families confronting previously untreatable neurogenetic diseases. The prospect of swiftly deployable, safe, and effective brain cell replacement therapy stands as a testament to innovation’s power to confront human suffering. While hurdles remain before clinical application, this work marks a pivotal stride toward conquering the neurological devastation wrought by lysosomal storage disorders.

Subject of Research: Brain microglia replacement therapy for lysosomal storage disorders (Tay-Sachs and Sandhoff diseases)

Article Title: Therapeutic genetic restoration through allogeneic brain microglia replacement

News Publication Date: 6-Aug-2025

Web References:
Stanford Medicine
Nature DOI Link

References:
Wernig, M., Mader, M., et al. (2025). Therapeutic genetic restoration through allogeneic brain microglia replacement. Nature. DOI: 10.1038/s41586-025-09461-6

Keywords: Stem cell implantation, Tay-Sachs disease, Neurodegenerative diseases, Microglia

Criticality, a notion borrowed from physics, describes systems poised exactly at the tipping point of transformation, where they are neither too rigidly ordered nor too erratically disorganized. In tangible terms, consider a sandpile steadily accumulating grains until an avalanche occurs; just before the avalanche, the pile exists in a fine-tuned critical state, exquisitely sensitive to the addition of the next grain. When applied to brain function, this framework suggests that neural networks operate near this critical threshold to maximize computational effectiveness, striking a balance that optimizes information processing and adaptability.

Hengen elaborates that the brain does not rely on hardwired, fixed circuits for its remarkably versatile behaviors—such as language acquisition, driving, or playing instruments—but instead must maintain a capacity to learn continually throughout life. Achieving and sustaining criticality allows the collective dynamics of neurons to flexibly adjust and recalibrate in response to new stimuli and environments. At this razor’s edge, the brain attains its highest computational power, capable of integrating sensory input, forming memories, and generating complex cognitive functions.

The theory also offers an illuminating perspective on neurological diseases like Alzheimer’s, which traditionally have been conceptualized as resulting from localized cell death or protein abnormalities. Hengen shifts the focus to the brain’s global computational state, asserting that neurodegeneration is fundamentally a breakdown in criticality. As criticality wanes, the brain’s ability to process and adapt deteriorates long before symptoms such as memory loss become evident, thus explaining why early disease stages are often invisible to conventional clinical assessments.

This insight emerges from collaborations with experts such as David M. Holtzman, whose groundbreaking work connects the accumulation of tau protein—one of Alzheimer’s disease’s pathological hallmarks—to disruptions in brain criticality. The decay of criticality offers a mechanistic explanation linking molecular pathology to cognitive collapse. It suggests that interventions targeting the restoration of criticality might halt or even reverse early disease progression, representing a paradigm shift in therapeutic strategies.

A notable advancement of this theoretical framework is its testability. Using functional MRI (fMRI) technology, researchers have devised mathematical metrics to quantify how close a person’s brain operates to the critical point. This capability holds immense potential for early diagnosis, allowing clinicians to detect subtle deviations in brain function years before overt clinical symptoms manifest. Coupled with emerging blood-based biomarkers, this approach could revolutionize preemptive disease management.

Beyond the realm of disease, criticality elucidates a fundamental attribute of brain function: the brain’s scale-invariance. Whether examining neural activity across milliseconds or months, or analyzing patterns from single neurons to entire cortical regions, criticality exhibits self-similarity. This fractal nature aligns coherently with subjective experience, where perception and cognition seem to transcend time scales seamlessly, consolidating millisecond events into lifelong narratives.

Sleep represents another vital facet of this theory. Through longitudinal studies, Hengen and physicist Ralf Wessel have unveiled that restorative sleep acts as a reset mechanism, reinstating the brain’s critical state which is gradually perturbed during wakefulness. This cyclical shift between wake-induced deviation from criticality and sleep-induced restoration underscores why insufficient sleep has profound cognitive consequences and increases susceptibility to neurological ailments.

This discovery dovetails with prior research showing that chronic sleep deprivation or disrupted circadian rhythms elevate Alzheimer’s risk. It also opens avenues for therapeutic interventions leveraging sleep to restore and maintain critical neural setpoints. Animal studies, such as those involving Alzheimer’s mouse models, demonstrate that targeted sleep enhancement can accelerate recovery of cognitive functions by reinforcing criticality, hinting at translational potential for humans.

Excitingly, criticality may explain individual differences in cognitive abilities. Ongoing investigations led by Hengen and colleagues indicate that newborns closer to criticality exhibit enhanced learning trajectories throughout childhood, anticipating educational outcomes. This biological baseline could demystify variations in intellectual aptitude that extend beyond genetics and environment, inviting new frameworks for personalized cognitive development strategies.

The interdisciplinary nature of this research—melding biology, physics, neuroscience, and psychology—exemplifies modern scientific collaboration, facilitated by institutions like Washington University in St. Louis. This synergy has catalyzed fresh perspectives and methodologies capable of approaching the brain’s complexity holistically rather than fragmentarily. As Hengen noted, the community’s collaborative spirit accelerates progress toward a unified conceptualization of brain function.

Ultimately, the criticality framework aspires to unify disparate strands of neuroscience into a cohesive theory of mind, with profound implications for medicine, education, and artificial intelligence. It envisions the brain as a living dynamical system fine-tuned by evolution to reside perpetually at a computational sweet spot—poised on the brink between chaos and order, where flexibility and stability coexist. While much remains to be elucidated, the theory’s explanatory power and testable nature position it to inspire scientific and public discourse alike.

As the brain science community begins to embrace the concept, fueled by compelling evidence and innovative imaging techniques, criticality might very well emerge as the guiding principle illuminating the intricate dance of neurons behind every thought, memory, and sensation. Such a unifying theory could revolutionize how we approach brain health, education, and artificial cognitive systems, ultimately transforming our understanding of what it means to think and learn.

Subject of Research: Brain Criticality and Its Role in Neural Computation and Disease
Article Title: Is criticality a unified setpoint of brain function?
News Publication Date: 23-Jun-2025
Web References:
– https://biology.wustl.edu/people/keith-hengen
– https://artsci.washu.edu/ampersand/what-is-brain-criticality-keith-hengen
– https://www.cell.com/neuron/fulltext/S0896-6273(25)00391-5
– https://pmc.ncbi.nlm.nih.gov/articles/PMC8073746/

References:
Hengen, K., Shew, W., et al. (2025). Is criticality a unified setpoint of brain function? Neuron. DOI: 10.1016/j.neuron.2025.05.020

Image Credits: Hengen and Shew, Neuron, 2025

Keywords

Brain Criticality, Neural Computation, Neuroscience, Alzheimer’s Disease, Functional MRI, Tau Protein, Sleep and Cognition, Neurodegenerative Disease, Dynamic Systems, Scale Invariance, Brain Function, Cognitive Development

Microglia constitute approximately 10% of the cells within the central nervous system, where they serve multifaceted roles from clearing infectious agents and cellular debris to sculpting neural circuits during brain development. Dysregulation of microglial function is increasingly recognized as a driver of neuroinflammation, which precedes and exacerbates hallmark protein aggregation in devastating disorders such as Alzheimer’s, Parkinson’s, Huntington’s diseases, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. Understanding microglial biology and manipulating their activity therapeutically has long been hampered by the scarcity of human cells and significant interspecies differences that limit rodent models’ translational reliability.

The core breakthrough rests on the use of TFome™—an innovative synthetic biology platform that systematically screens and applies combinations of human transcription factors (TFs) to steer iPSC fate decisions with remarkable precision and speed. Transcription factors are proteins that act as master regulators driving entire gene expression networks, thereby orchestrating cellular identity and function. Prior to this study, attempts to cultivate microglia-like cells from stem cells were inefficient, protracted, and often yielded immature or functionally limited cells. Employing iterative rounds of TF screening and single-cell RNA sequencing (scRNA-seq), the Wyss-HMS team distilled a potent sextet of microglia-specifying TFs that unlock rapid differentiation and maturation in only four days.

The researchers initiated the process by curating a smartly selected panel of 40 candidate TFs, informed by developmental biology and disease-specific expression profiles characteristic of primary human microglia. By randomly expressing combinations of five to seven TFs in single iPSCs and assessing their genetic profiles through scRNA-seq, the team identified a triumvirate of TFs—SPI1, CEBPA, and FLI1—that induced partial microglial programming. Recognizing that this initial combination was insufficient for full functional maturation, the group supplemented the cocktail with three additional TFs—MEF2C, CEBPB, and IRF8—elevating the cellular phenotype to closely match native microglia both transcriptionally and morphologically.

Crucially, these engineered microglia-like cells exhibited hallmark responses to neuroinflammatory stimuli, a fundamental functional test. Exposure to interferon gamma (IFNγ), a cytokine elevated during brain infections and neurodegenerative states, provoked activation of microglia-specific gene expression programs. Remarkably, the aggregates of TDP-43 protein—a pathological feature in ALS—similarly elicited microglial gene expression changes, underscoring the physiological relevance of these stem cell-derived microglia surrogates.

The implications of this technology extend far beyond mere cell culture convenience. By expediting the derivation of highly functional human microglia, the TFome™ platform empowers researchers to faithfully model neuroinflammatory processes implicated in myriad neurological diseases. It paves the way for high-throughput drug screening, mechanistic exploration, and personalized medicine interventions with patient-specific iPSC lines. Moreover, the modularity and adaptability of TFome™ technology portend its application to other elusive cell types, potentially revolutionizing regenerative medicine and cell therapy product development.

This advance builds upon prior work in which the Wyss Institute team developed a comprehensive library of 1,732 human transcription factors and variants, laying the foundation for precision control of stem cell fates. Notably, the founders also established GC Therapeutics, a biotechnology startup aiming to translate transcription factor-based cell engineering into commercially viable cell therapies. The current study signifies a major refinement of their platform, showcasing iterative design and data-driven optimization harnessed by single-cell transcriptomics to achieve rapid and target-specific cellular identity.

Underlying this cellular engineering feat is an integrated interdisciplinary effort combining synthetic biology, computational genomics, bioinformatics, and neural cell biology. Collaborators included experts in statistics and single-cell data analysis who developed algorithms to rank TF combinations by their effectiveness in recapitulating authentic microglial gene expression signatures. Such iterative screening—cycling through design, experimental testing, and computational validation—proved essential to identifying the optimal transcriptional code for human microglia induction.

The team’s focus on microglia originated from a longstanding interest in creating complex brain organoids—three-dimensional miniaturized tissue models—which aim to recapitulate cellular diversity and functional intercellular interactions present in the human brain. While TFome™ technology had allowed generation of neuronal, oligodendrocyte, stromal, and vascular components of brain organoids, microglia presented a tougher challenge due to their unique developmental origins and transcriptional programs. Addressing this gap enhances the physiological relevance of brain organoids, expanding their utility in modeling neurodevelopment, neurodegeneration, and neuroinflammation.

Looking forward, the researchers envision fine-tuning TF expression dynamics—varying timing, dosage, and sequence—to engineer microglia subtypes with specialized activities. This precision could unravel cell-type-specific contributions to brain pathologies and enable targeted interventions that modulate particular microglial functions. Their approach exemplifies a synthetic biology paradigm in which modular genetic parts enable custom design of complex cellular phenotypes within unprecedented timeframes.

In sum, this iterative transcription factor screening method exemplifies a leap forward in stem cell biology and neuroimmunology. By successfully producing microglia-like cells that combine rapid generation with mature, functionally relevant profiles, investigators have unlocked a promising new avenue for studying brain immune cells and their roles in health and disease. As neurodegenerative disorders continue to exact a growing global toll, innovative tools such as this offer fresh hope for decoding disease mechanisms and discovering effective therapeutics.

Subject of Research: Cells

Article Title: Iterative transcription factor screening enables rapid generation of microglia-like cells from human iPSC

News Publication Date: 10-Jun-2025

Web References:

• Wyss Institute at Harvard University: https://wyss.harvard.edu/
• Harvard Medical School: https://hms.harvard.edu/
• GC Therapeutics: https://www.gc-tx.com/
• TFome™ technology Nature publication: https://www.nature.com/articles/s41587-020-0742-6
• CircaVent drug discovery platform: https://wyss.harvard.edu/technology/circavent-a-drug-discovery-platform-for-mental-health-conditions/

References:
Liu, S., Zhang, F., Li, L., et al. Iterative transcription factor screening enables rapid generation of microglia-like cells from human iPSC. Nature Communications. 2025 Jun 10.

Image Credits: Wyss Institute at Harvard University